দেশ: কানাডা
ভাষা: ইংরেজি
সূত্র: Health Canada
CODEINE PHOSPHATE; CAFFEINE; ACETAMINOPHEN
JANSSEN INC
N02AJ06
CODEINE AND PARACETAMOL
15MG; 15MG; 300MG
TABLET
CODEINE PHOSPHATE 15MG; CAFFEINE 15MG; ACETAMINOPHEN 300MG
ORAL
500
Narcotic (CDSA I)
OPIATE AGONISTS
Active ingredient group (AIG) number: 0311391001; AHFS:
CANCELLED POST MARKET
2020-09-25
_~db5_O33947f74e3dd4b8cbc967bc45698f0af.docx _ _ _ _EDMS-RIM-569056 v2.0 _ _Page 1 of 40 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION N TYLENOL ® WITH CODEINE NO. 2 acetaminophen, caffeine and codeine phosphate tablets 300 mg acetaminophen, 15 mg caffeine and 15 mg codeine phosphate tablets N TYLENOL ® WITH CODEINE NO. 3 acetaminophen, caffeine and codeine phosphate tablets 300 mg acetaminophen, 15 mg caffeine and 30 mg codeine phosphate tablets Analgesic-Antipyretic Janssen Inc. 200 Whitehall Drive Markham, Ontario L3R 0T5 www.janssen.com/canada Date of Revision: December 1, 2021 SUBMISSION CONTROL NO: 258437 All trademarks used under license. © 2021 Janssen Inc. _~db5_O33947f74e3dd4b8cbc967bc45698f0af.docx _ _ _ _EDMS-RIM-569056 v2.0 _ _Page 2 of 40 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................3 INDICATIONS AND CLINICAL USE .........................................................................3 CONTRAINDICATIONS .............................................................................................3 WARNINGS AND PRECAUTIONS .............................................................................5 ADVERSE REACTIONS............................................................................................ 15 DRUG INTERACTIONS ............................................................................................ 17 DOSAGE AND ADMINISTRATION ......................................................................... 18 OVERDOSAGE ......................................................................................................... 21 ACTION AND CLINICAL PHARMACOLOGY......................................................... 24 STORAGE AND STABILITY .................................................................................... 26 SPECIAL HANDLING INSTRUCTIONS .................................................. সম্পূর্ণ নথি পড়ুন